Upregulation of the NEK2/TUFT1 axis in breast cancer is associated with poor outcomes, implying that for the cancer cell population the disadvantage conferred by TUFT1 hyperphosphorylation on cell proliferation may be overcome by its advantage of increasing CA and CIN. This evidence concerns the gene TUFT1 and breast carcinoma.